Aggarwal Bhumika, Gogtay Jaideep
Medical Services, Cipla Ltd, Mumbai, India.
Expert Rev Respir Med. 2014 Jun;8(3):349-56. doi: 10.1586/17476348.2014.905916. Epub 2014 May 7.
The inhaled route is considered to be the best route to administer drugs for treating respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), for both safety and efficacy. Inhalation devices are classified into four types - pressuriszed metered dose inhalers (pMDIs), dry powder inhalers, breath actuated inhalers and nebulizers. pMDIs are portable, convenient, multi-dose devices and these advantages have made them very popular with patients. They were introduced in the 1950s as the first portable, multi-dose delivery system for bronchodilators. Even though pMDIs are the most widely used devices for inhalation therapy in asthma and COPD, studies establishing their use and providing clinical data with bronchodilators and combination therapies in patients with COPD are limited. A summary of the use of pMDI with spacers in patients with COPD in terms of lung deposition and impact on lung function are presented in this review article. A review of use of the pMDI device in patients with COPD with different available and prescribed medications (bronchodilators-β2-agonists and anticholinergics, and their combination with inhaled corticosteroids) is discussed.
从安全性和有效性两方面考虑,吸入途径被认为是治疗哮喘和慢性阻塞性肺疾病(COPD)等呼吸道疾病给药的最佳途径。吸入装置分为四类——压力定量吸入器(pMDIs)、干粉吸入器、呼吸驱动吸入器和雾化器。pMDIs是便携式、方便的多剂量装置,这些优点使其在患者中非常受欢迎。它们于20世纪50年代作为第一种用于支气管扩张剂的便携式多剂量给药系统被引入。尽管pMDIs是哮喘和COPD吸入治疗中使用最广泛的装置,但关于其在COPD患者中使用并提供支气管扩张剂和联合疗法临床数据的研究有限。本文综述了pMDI加储雾罐在COPD患者中的使用情况,包括肺沉积及对肺功能的影响。还讨论了pMDI装置在使用不同可用和处方药物(支气管扩张剂——β2激动剂和抗胆碱能药物,以及它们与吸入性糖皮质激素的联合使用)的COPD患者中的应用。
Expert Rev Respir Med. 2014-6
Acta Biomed. 2007-12
Int J Chron Obstruct Pulmon Dis. 2015-10-29
COPD. 2013-3-28
Mater Today Bio. 2024-1-22
NPJ Prim Care Respir Med. 2016-6-16